Murine T lymphocytes incapable of producing macrophage inhibitory protein-1α are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier

Blood

Volumn 93, Issue 1, 1999, Pages 43-50

  Serody, Jonathan S ^a   Cook, Donald N ^b   Kirby, Suzanne L ^b   Reap, Elizabeth ^b   Shea, Thomas C ^b   Frelinger, Jeffrey A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

EID: 0032915402     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.1.43     Document Type: Article

References (49)

1. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Soegiarso W, Brodsky I: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
2. Jones RJ: Biology and treatment of chronic myeloid leukemia. Curr Opin Oncol 9:3, 1997
3. Levitt L, Lin R: Biology and treatment of adult acute lymphoblastic leukemia. West J Med 164:143, 1996
4. Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G: Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol 12:141, 1994
5. Bierman PJ: Update of results of autologous bone marrow transplantation in lymphoma. Med Oncol 11:35, 1994
6. Gribben JG: Bone marrow transplantation for low-grade B-cell malignancies. Curr Opin Oncol 9:117, 1997
7. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 10:1682, 1992
8. Schlaifer D, Attal M, Huguet F, Canal P, Laurent G, Pris J: Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation. Semin Hematol 31:31, 1994
9. Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL, Rubinsak JR, Essell JH, Halvorson RD, Thompson JM: Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: A dose-finding study. Bone Marrow Transplant 14:595, 1994
10. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH: Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: Those transplanted with active CNS disease have a poor outcome - A report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 12:2415, 1994
11. O'Marcaigh AS, Cowan MJ: Bone marrow transplantation for inherited diseases. Curr Opin Oncol 9:126, 1997
12. Blazar BR, Korngold R, Vallera DA: Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 157:79, 1997
13. Chao NJ, Schlegel PG: Prevention and treatment of graft-versus-host disease. Ann NY Acad Sci 770:130, 1995
14. Lazarus HM, Vogelsang GB, Rowe JM: Prevention and treatment of acute graft-versus-host disease: The old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 19:577, 1997
15. Marcellus DC, Vogelsang GB: Graft-versus-host disease. Curr Opin Oncol 9:131, 1997
16. Vogelsang GB: Graft-versus-host disease: Implications from basic immunology for prophylaxis and treatment. Cancer Treat Res 77:87, 1997
17. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476, 1995
18. Henkart PA: Lymphocyte-mediated cytotoxicity: Two pathways and multiple killer molecules. Immunity 1:343, 1994
19. Graubert TA, DiPersio JF, Russell JH, Ley TJ: Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100:904, 1997
20. Blazar BR, Taylor PA, Vallera DA: CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64:571, 1997
21. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
22. Via CS, Rus V, Nguyen P, Linsley P, Gause WC: Differential effect of CTLA4-Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 157:4258, 1996
23. Rollins BJ: Chemokines. Blood 90:909, 1997
24. Kunkel SL, Stricter RM, Lindley IJ, Westwick J: Chemokines: New ligands, receptors and activities. Immunol Today 16:559, 1995
25. Negus RP: The chemokines: Cytokines that direct leukocyte migration. J R Soc Med 89:312, 1996
26. Taub DD, Oppenheim JJ: Chemokines, inflammation and the immune system. Ther Immunol 1:229, 1994
27. Baggiolini M, Dewald B, Moser B: Human chemokines: An update. Annu Rev Immunol 15:675, 1997
28. Campbell JJ, Qin S, Bacon KB, Mackay CR, Butcher EC: Biology of chemokine and classical chemoattractant receptors: Differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J Cell Biol 134:255, 1996
29. Graves DT, Jiang Y: Chemokines, a family of chemotactic cytokines. Crit Rev Oral Biol Med 6:109, 1995
30. Cook DN: The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 59:61, 1996
31. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O: Requirement of MIP-1α for an inflammatory response to viral infection. Science 269:1583, 1995
32. + T cells are a biologically relevant source of MIP-1α in vivo. (submitted)
33. Reap EA, Sobel ES, Jennette JC, Cohen PL, Eisenberg RA: Conventional B cells, not B1 cells, are the source of autoantibodies in chronic graft-versus-host disease. J Immunol 151:7316, 1993
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
35. Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, Vallera DA: Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. J Immunol 157:3250, 1996
36. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ: Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 59:81, 1996
37. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811, 1995
38. Moser B: Chemokines and HIV: A remarkable synergism. Trends Microbiol 5:88, 1997
39. Tedla N, Palladinetti P, Kelly M, Kumar RK, DiGirolamo N, Chattophadhay U, Cooke B, Truskett P, Dwyer J, Wakefield D, Lloyd A: Chemokines and T lymphocyte recruitment to lymph nodes in HIV infection. Am J Pathol 148:1367, 1996
40. Vicenzi E, Biswas P, Mengozzi M, Poli G: Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol 62:34, 1997
41. Taub DD, Lloyd AR, Wang JM, Oppenheim JJ, Kelvin DJ: The effects of human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol 351:139, 1993
42. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ: Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-1β. Science 260:355, 1993
43. Schall TJ, Bacon K, Camp RDR, Kaspari JW, Goeddel DV: Human macrophage inflammatory protein a (MIP-1α) and MIP-1β chemokines attract distinct populations of lymphocytes. J Exp Med 177:1821, 1993
44. Bradley DS, Jennette JC, Cohen PL, Eisenberg RA: Chronic graft versus host disease-associated autoimmune manifestations are independently regulated by different MHC class II loci. J Immunol 152:1960, 1994
45. Morris SC, Cheek RL, Cohen PL, Eisenberg RA: Autoantibodies in chronic graft versus host result from cognate T-B interactions. J Exp Med 171:503, 1990
46. Morris SC, Cheek RL, Cohen PL, Eisenberg RA: Allotypespecific immunoregulation of autoantibody production by host B cells in chronic graft-versus host disease. J Immunol 144:916, 1990
47. Weido AJ, Reece LM, Simm TC: Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. Ann Allergy Asthma Immunol 77:407, 1996
48. Taub DD: Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev 7:355, 1996
49. Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Stricter RM: Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 59:24, 1996